Literature DB >> 3748008

[3H]Dihydrotetrabenazine binding to bovine striatal synaptic vesicles.

J A Near.   

Abstract

[2-3H]Dihydrotetrabenazine (2-hydroxy-3-isobutyl-9, 10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine) bound to a single class of binding sites in synaptic vesicles isolated from bovine corpus striatum, with an apparent dissociation constant (Kd) of 2.3 nM and a Bmax of 15.1 pmol/mg of protein determined at equilibrium. Kinetic determination of the equilibrium dissociation constant yielded a value of 5.4 nM. ATP had no effect on the apparent Kd or Bmax, nor did it alter the kinetics of association or dissociation. Dopamine, serotonin, and other substrates for transport into synaptic vesicles inhibited binding at concentrations that were several orders of magnitude higher than their Km values for transport in the presence of ATP. The potent uptake blocker reserpine inhibited with a Ki of 340 nM in the absence of ATP, but biphasic inhibition, with Ki values of 3.2 and 345 nM, was observed in the presence of ATP. With incubation times of 24 hr, the potency of reserpine as an inhibitor of binding in the absence of ATP is increased by 1 to 2 orders of magnitude, implying a slow association rate for reserpine in the absence of nucleotide. These results suggest that dihydrotetrabenazine interacts with the catecholamine/serotonin porter in synaptic vesicles, although the binding site is probably not identical to that involved in active transport of substrate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3748008

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  9 in total

1.  Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; Guangrong Zheng; Agripina G Deaciuc; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2010-09-28       Impact factor: 4.030

2.  Profound neuronal plasticity in response to inactivation of the dopamine transporter.

Authors:  S R Jones; R R Gainetdinov; M Jaber; B Giros; R M Wightman; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

Review 3.  The tyramine binding site in the central nervous system: an overview.

Authors:  A Vaccari
Journal:  Neurochem Res       Date:  1993-08       Impact factor: 3.996

4.  GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.

Authors:  David B Horton; Justin R Nickell; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin
Journal:  J Neurochem       Date:  2013-08-19       Impact factor: 5.372

5.  Potent, extra-channel influence of several calcium-channel modulators on striatal binding of [3H]tyramine.

Authors:  A Vaccari; P Saba; G Gessa
Journal:  Neurochem Res       Date:  1993-11       Impact factor: 3.996

Review 6.  Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.

Authors:  Thomas S Guillot; Gary W Miller
Journal:  Mol Neurobiol       Date:  2009-03-04       Impact factor: 5.590

7.  Mathematical insights into the effects of levodopa.

Authors:  Michael C Reed; H Frederik Nijhout; Janet A Best
Journal:  Front Integr Neurosci       Date:  2012-07-04

8.  DOPA Homeostasis by Dopamine: A Control-Theoretic View.

Authors:  Rune Kleppe; Qaiser Waheed; Peter Ruoff
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

9.  Homeostatic mechanisms in dopamine synthesis and release: a mathematical model.

Authors:  Janet A Best; H Frederik Nijhout; Michael C Reed
Journal:  Theor Biol Med Model       Date:  2009-09-10       Impact factor: 2.432

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.